BA
IBB icon

Blueline Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Blueline Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Buy
+46
New +$7.91K ﹤0.01% 205

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Blueline Advisors's IBB Position: Q2 2026 in Review

Blueline Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 46 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #205 among its holdings.

954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Blueline Advisors held 46 shares of iShares Biotechnology ETF worth $7K as of Q2 2026.
  • iShares Biotechnology ETF was a new Blueline Advisors position in Q2 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Blueline Advisors's portfolio in Q2 2026, its #205 holding.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Blueline Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.